The Cost-Effective Analysis of a Rotavirus Immunization Program for the United States

The “Cost-effectiveness Analysis of a Rotavirus Immunization Program for the United States” was designed to estimate the economic impact of a national rotavirus immunization program. The research question and objective of the analysis was to determine if a rotavirus vaccine immunization program would be beneficial and cost effective. The study is policy relevant because it will determine if a rotavirus vaccine immunization program is effective enough for implementation and will assist in setting

A very controversial issue these days is whether or not to receive immunizations. I am a young mother and I tend to follow my mothers and doctors’ advice when it comes to mine and my children’s health, I feel as though my doctor has the best advice on how I can keep us all happy and healthy, however this is not the case for everyone. Many questions have arisen about immunizations and there are quite a few people who are either hesitant to or will not have themselves and their children immunized.

group of people that don’t mind exposing their children to serious harm; in recent years, many adults have decided against vaccinating their children. This is unusual, as vaccines are non-lethal, very safe protection for children; they are even cost-effective for their parents and are considerably safer for the entire family when these children are vaccinated routinely (Prosser, 1548). Jennifer Hamborsky of the Centers for Disease Control and Prevention essentially describes vaccination as the administration

Vaccination policy Analysis Adriana Ortega Benjamin Tetteh Ramona Abou Habib Saera Sultana PUAD 6260-01 Healthcare Policy Analysis Professor Farida Sultana July 27, 2015 Table of Contents I. Executive Summary 3 II. Introduction 4 III. Examination and Analysis of the Policy 5 A. Background 5 B. Involvement and Work of Lobbying Groups 5 C. Analysis: Pros and Cons 6 D. Analysis: Evaluation Methods 10 E. Outcomes 11 IV. Conclusion 12 References 13 I. Executive Summary Vaccination policy

found that while 94% of individuals surveyed had vaccinated or plan on vaccinating their children, only 23% of participants had no concerns about the vaccines16. This reiterates the point that even though there are high rates of vaccination in the United States, this should not be taken as there are high confident rates in the safety of vaccines16. No medical intervention comes completely risk free. However, when looking at the potential risk for any medical intervention it is important to look at this

both supply and demand side interventions. Vaccine availability has been limited by the number of suppliers, high R&D and production costs, and safety problems leading to increased regulatory requirements. Demand has been constrained by rapidly increasing vaccine costs, financing issues that have constrained efforts to achieve targets set for population immunization rates, and parental attitudes regarding the safety and efficacy of vaccine products. To date, governments, in concert with public health

additional operational headquarters in the USA Global presence: about 160 countries Primary markets: USA, France, Germany, UK, Italy and Japan Employees: approximately 103,000 GSK key figures for 2003 (in £ million) Sales 21,441 Materials and production costs 4,188 Marketing and administration 7,563 R&D expenditures 2,770 Operating income 6,920 Net profit 4,765 GSK has two main business divisions, pharmaceuticals and consumer healthcare. This profile deals with the pharmaceuticals division, which generates